(Nirsevimab)Biosimilar Reference Antibody-GS40476 新品

货号：GS40476

Nirsevimab is a human IgG1κ monoclonal antibody developed for prophylaxis against respiratory syncytial virus (RSV) in infants and young children. It targets the prefusion conformation of the RSV fusion (F) glycoprotein, binding to a highly conserved epitope with high affinity. This binding neutralizes the virus, preventing infection of respiratory epithelial cells. Engineered with an extended half‑life (via YTE mutations in the Fc region), nirsevimab provides long‑lasting protection with a single intramuscular dose. It is approved in multiple regions (including the US, EU, UK) for the prevention of RSV‑associated lower respiratory tract disease in neonates and infants during their first RSV season, and for children up to 24 months of age who remain vulnerable.